Patient Guide: A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 6 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT04639180
Status: ACTIVE_NOT_RECRUITING
Condition: Hepatocellular Carcinoma (HCC)
Phase: PHASE3

Find a Study Location Near You

This study is available at 6 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Chongqing, Chongqing Municipality
  • Nanjin, Guangzhou
  • Guiyang, Guizhou
  • • And 3 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily